Earnings And MarginsAdjusted EBITDA margin expanded +50bps y/y to 15.5%, driven by lower supply costs and procurement and revenue cycle initiatives.
Revenue GrowthStrong s-s case growth trends were the highlight of the quarter, coupled with stable pricing growth that supported solid ~+10% s-s revenue growth.
Strategic InitiativesThe company continues to execute on its strategy of targeting higher-acuity procedures, as illustrated by its deployment of $220mm on musculoskeletal facility acquisitions in the quarter.